A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Monosomy 7/deletion 7q by FISH : 1001110
Test CodeMDFCPCMONO7 or 1001110
Alias/See Also
D7S486; 7q-; cen7
CPT Codes
88271x2, 88275
Instructions
Bone Marrow aspirate in a green top sodium heparin tube (2-3 mL) or Peripheral Blood in a green top sodium heparin tube (2-10 mL).
Transport Container
Blood or Bone Marrow: Do not centrifuge.
Transport Temperature
Blood or Bone Marrow: Ambient temperature within 24 hours. Specimen can be refrigerated if not transported immediately. Do not freeze. Protect from heat with a cold pack.
Specimen Stability
Blood and Bone Marrow: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology
Fluorescence in situ hybridization (FISH)
Setup Schedule
Monday - Friday
Report Available
Up to 7 days
Limitations
Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Reference Range
An interpretive report will be provided.
Clinical Significance
Deletions of the long arm of chromosome 7(7q-) are commonly observed in MDS and AML, especially in patients with previous exposure to mutagenic agents or radiation therapy. These deletions have been associated with susceptibility to infections, rapid disease progression, and a poor response to therapy. Additionally, deletions of 7q31 are seen in about 40-45% of splenic marginal zone B-cell lymphomas compared to about 8% of other B-cell lymphoproliferative syndromes. A recent study states that 7q deletions in splenic marginal zone B-cell lymphomas are associated with a more aggressive clinical course.
Performing Laboratory
med fusion